Eledon Pharmaceuticals Advances Tegoprubart with Positive Clinical Data and Orphan Drug Designation
Event summary
- Eledon Pharmaceuticals reported positive 24-month follow-up data from a Phase 1b long-term extension study of tegoprubart in kidney transplantation, showing no episodes of biopsy-proven acute rejection or graft loss.
- Tegoprubart received Orphan Drug designation from the FDA for the prevention of allograft rejection in liver transplantation, adding to its existing designations for pancreatic islet cell transplantation and ALS.
- Updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation showed 100% insulin independence in 10 patients with a mean HbA1c of 5.35%.
- Eledon anticipates multiple milestones in 2026, including regulatory engagement for Phase 3 development in kidney transplantation and the initiation of clinical trials in liver and islet transplantation.
The big picture
Eledon Pharmaceuticals is positioning tegoprubart as a next-generation immunosuppressive therapy with broad applications across multiple transplantation settings. The positive clinical data and Orphan Drug designations underscore its potential to address key safety and efficacy issues with current standard-of-care treatments. The company's strategic focus on advancing tegoprubart through multiple clinical trials reflects its ambition to become a leader in transplantation therapies.
What we're watching
- Regulatory Pathway
- Whether the FDA guidance on Phase 3 trial design for tegoprubart in kidney transplantation will accelerate its path to market.
- Clinical Validation
- The pace at which long-term data from Phase 1 and Phase 2 BESTOW studies will reinforce tegoprubart's safety and efficacy profile.
- Market Expansion
- How the initiation of new clinical trials in liver and islet transplantation will broaden tegoprubart's therapeutic potential.
Related topics